研发管线

在早期拦截疾病,不断攀登新的高峰

Pipeline MiRXES 2021 MiRXES 2021年管线

解决整个连贯护理过程中未被填补的临床需求 解决在疾病全病程管理中仍尚待满足的临床需求

癌症早期阻断途径 癌症早筛管线

癌症早期检测

•RNA科技驱动 的多癌种、多组学筛查检测。

+ 首先推出胃癌筛查检测。

+ 肺癌筛查检测将于 2021 年年底推出。

+ 随后推出结直肠癌、肝癌、乳腺癌、胰腺癌和卵巢癌检测。

癌症精准诊断

•检测周期短,指导癌症治疗方案,耐药预测。

+ 为APEX提供组织活检和液体活检服务,检测周期仅四天。

+ 随后将推出针对全基因组分析、免疫治疗、血液学-肿瘤学以及体细胞突变的检测。

疾病早期检测管线

非肿瘤诊断产品

•传染病、心血管疾病和代谢性疾病的多组学早期诊断和伴随诊断检测。

+ Fortitude COVID-19 RT-PCR 测试和大流行支持,提供一整套测试解决方案。
+ 依次介绍肺动脉高压、心力衰竭和胰岛素抵抗的测试。

癌症早期阻断途径 癌症早筛管线

癌症早期检测

•RNA科技驱动 的多癌种、多组学筛查检测。

+ 首先推出胃癌筛查检测。

+ 肺癌筛查检测将于 2021 年年底推出。

+ 随后推出结直肠癌、肝癌、乳腺癌、胰腺癌和卵巢癌检测。

症精准诊断

•检测周期短,指导癌症治疗方案,耐药预测。

+ 为APEX提供组织活检和液体活检服务,检测周期仅四天。

+ 随后将推出针对全基因组分析、免疫治疗、血液学-肿瘤学以及体细胞突变的检测。

疾病早期检测管线

Non-oncology Diagnostics

•传染病、心血管疾病和代谢性疾病的多组学早期诊断和伴随诊断检测。

+ 首先推出胃癌筛查检测。

+  2021 年年底将推出肺癌筛查检测。

+ 随后推出结直肠癌、肝癌、乳腺癌、胰腺癌和卵巢癌检测

The continuum of care:

在此我们最新动态和重要的科学论文。了解更多.我们最新动态和重要的科学论文。

24 Mar 2021

Mammography is extensively used for breast cancer screening but has high false-positive rates. This paper describes the discovery, development, and validation of a serum 6-miRNA panel to discriminate between malignant and benign breast lesions among women with abnormal mammograms.

24 Feb 2021

Cross-platform evaluation study led by Merck (MSD) scientists showing that MiRXES ID3EAL miRNA qPCR platform has superior reproducibility and detection rate compared to other commercial miRNA profiling platforms (Exiqon qPCR, Qiagen qPCR, Applied Biosystems qPCR, NanoString nCounter, and miRNA-Seq) when used for discovery and validation of blood-based miRNA biomarkers.

24 Feb 2021

Cross-platform evaluation study led by Merck (MSD) scientists showing that MiRXES ID3EAL miRNA qPCR platform has superior reproducibility and detection rate compared to other commercial miRNA profiling platforms (Exiqon qPCR, Qiagen qPCR, Applied Biosystems qPCR, NanoString nCounter, and miRNA-Seq) when used for discovery and validation of blood-based miRNA biomarkers.

24 Feb 2021

Cross-platform evaluation study led by Merck (MSD) scientists showing that MiRXES ID3EAL miRNA qPCR platform has superior reproducibility and detection rate compared to other commercial miRNA profiling platforms (Exiqon qPCR, Qiagen qPCR, Applied Biosystems qPCR, NanoString nCounter, and miRNA-Seq) when used for discovery and validation of blood-based miRNA biomarkers.

24 Feb 2021

Cross-platform evaluation study led by Merck (MSD) scientists showing that MiRXES ID3EAL miRNA qPCR platform has superior reproducibility and detection rate compared to other commercial miRNA profiling platforms (Exiqon qPCR, Qiagen qPCR, Applied Biosystems qPCR, NanoString nCounter, and miRNA-Seq) when used for discovery and validation of blood-based miRNA biomarkers.

24 Feb 2021

Cross-platform evaluation study led by Merck (MSD) scientists showing that MiRXES ID3EAL miRNA qPCR platform has superior reproducibility and detection rate compared to other commercial miRNA profiling platforms (Exiqon qPCR, Qiagen qPCR, Applied Biosystems qPCR, NanoString nCounter, and miRNA-Seq) when used for discovery and validation of blood-based miRNA biomarkers.

版权所有 © 2022 MiRXES Pte Ltd. 保留所有权利。| 隐私政策
Scroll to Top